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Abstract: The Danish study of Functional Disorders (DanFunD) cohort was initiated to 
outline the epidemiology of functional somatic syndromes (FSS) and is the first larger coor-
dinated epidemiological study focusing exclusively on FSS. FSS are prevalent in all medical 
settings and can be defined as syndromes that, after appropriate medical assessment, cannot 
be explained in terms of a conventional medical or surgical disease. FSS are frequent and 
the clinical importance varies from vague symptoms to extreme disability. No well-described 
medical explanations exist for FSS, and how to delimit FSS remains a controversial topic. 
The specific aims with the cohort were to test delimitations of FSS, estimate prevalence and 
incidence rates, identify risk factors, delimitate the pathogenic pathways, and explore the 
consequences of FSS. The study population comprises a random sample of 9,656 men and 
women aged 18–76 years from the general population examined from 2011 to 2015. The 
survey comprises screening questionnaires for five types of FSS, ie, fibromyalgia, whiplash-
associated disorder, multiple chemical sensitivity, irritable bowel syndrome, and chronic fatigue 
syndrome, and for the unifying diagnostic category of bodily distress syndrome. Additional 
data included a telephone-based diagnostic interview assessment for FSS, questionnaires on 
physical and mental health, personality traits, lifestyle, use of health care services and social 
factors, and a physical examination with measures of cardiorespiratory and morphological 
fitness, metabolic fitness, neck mobility, heart rate variability, and pain sensitivity. A biobank 
including serum, plasma, urine, DNA, and microbiome has been established, and central 
registry data from both responders and nonresponders are similarly available on morbidity, 
mortality, reimbursement of medicine, heath care use, and social factors. A complete 5-year 
follow-up is scheduled to take place from year 2017 to 2020, and further reexaminations 
will be planned. Several projects using the DanFunD data are ongoing, and findings will be 
published in the coming years.
Keywords: functional somatic syndromes, medically unexplained symptoms, epidemiology, 
longitudinal cohort study, pathophysiology, risk factors
Introduction
The Danish study of Functional Disorders (DanFunD) was initiated to outline the 
epidemiology of what is often referred to as medically unexplained symptoms/syn-
dromes or bodily distress, defined as conditions that cannot be explained in terms of 
a conventional medical or surgical disease.1–6 They exist in many forms, are clinically 
important, and are prevalent in all medical settings. The common name for these 
conditions has been interchanging but will in this article be referred to as functional 
somatic syndromes (FSS), represented by irritable bowel syndrome,7–10 fibromyalgia,11 
chronic fatigue syndrome,12–14 whiplash-associated disorders,15 multiple chemical 
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sensitivity,16 and the unifying diagnostic category of bodily 
distress syndrome.6,17
A fundamental prerequisite for a rational handling of 
chronic diseases is a detailed knowledge of the epidemiology 
of the diseases, which is severely lacking in regard to FSS. A 
major epidemiological breakthrough came with the Framing-
ham Heart Study (1948–1952), which signifies the foundation 
of the process that led toward our current understanding of 
the occurrence, major risk factors, and prognosis for cardio-
vascular diseases.18–20 Today, >60 years after these first cohort 
studies, we have an extensive knowledge on the epidemiology 
of many chronic diseases (cardiovascular diseases, diabetes, 
lung diseases, and certain cancers), which has led to a solid 
basis for both rational prevention and treatment.18,20 In spite 
of this obvious success, the medical fields encompassing 
the different FSS have not been through such a process yet. 
Important obstacles are the unclear nosological status of FSS 
and the ongoing dispute of whether FSS constitute one or 
several disorders.11 Within the recent years, epidemiological 
studies of FSS have contributed with valuable new knowledge 
about FSS.21–25 However, important epidemiological weak-
nesses of these studies are present, such as recruiting only 
patients suffering from one single FSS subtype, not using a 
random sample of the general population or basing the FSS 
diagnosis on questionnaire data exclusively. Consequently, 
the estimated prevalence and the incidence rates of FSS have 
so far been inconsistent,26,27 and our understanding of both 
the pathogenesis and common risk factors is similarly at a 
premature stage.28,29 The significance of various physiologi-
cal, biochemical, and psychological factors has received some 
scientific attention,30–34 but a systematic approach has been 
missing. Finally, the impact of FSS both on an individual 
level and for the society as a whole is difficult to disentangle 
due to few well-conducted follow-up studies.
The burden on the use of the health care system itself 
can be calculated indirectly, but there is a need for longitu-
dinally cohort studies linked to registries to obtain reliable 
data on remission, exacerbation, use of health care services, 
and development of other diseases. Accordingly, due to 
the current lack of medical explanations for FSS, patients 
are often misdiagnosed and offered insufficient health care 
solutions.5,35 Moreover, they experience being met with 
mistrust and doubt by health care professionals, the social 
welfare system, and friends and relatives.16,30 The negative 
consequences for the patients and society in terms of unmet 
health care needs, social isolation, and loss of ability to work 
emphasize the demand for well-designed studies investigating 
the epidemiology.26
In 2009, motivated by the growing concern about the FSS 
within the medical community, a “think tank” of scientists, 
medical experts, and medical social workers were invited 
by the Danish foundation TrygFonden to discuss possible 
interdisciplinary and cross-national research studies. The 
outcome was the formation of the DanFunD Steering Com-
mittee with the overall objectives to design and launch a 
large-scale epidemiological population-based longitudinal 
study with special focus on FSS, encompassing research-
ers from basic science, clinical science, biostatistics, and 
epidemiology.
Objectives
The overall goal of the DanFunD is to unravel the epidemiol-
ogy of FSS and achieve a similar knowledge to what has been 
generated for other chronic diseases using epidemiological 
methods.
More specifically, the objectives of the DanFunD can be 
divided into the following categories:
1. To delimitate FSS by means of relevant symptoms in 
the general population. This will lead to a deeper under-
standing as to whether we are dealing with one or several 
disorders and bring forward more transparent delimita-
tions of FSS. A better delimitation of FSS will similarly 
lead to more precise estimates of the true prevalence and 
incidence of FSS.
2. To disentangle the pathophysiology of FSS, thereby sup-
porting the delimitation of the syndrome(s).
3. To identify risk factors for FSS ranging from the genome 
and the microbiomes over fitness and lifestyles to psy-
chological factors.
4. To assess the consequences of FSS, both on an individual 
level and for the society as a whole, including the course 
of the syndromes (remission, stability, and exacerba-
tion), development of other diseases, and socioeconomic 
consequences.
Study population
The DanFunD cohort is anchored at the Research Centre 
for Prevention and Health (RCPH), Glostrup, Denmark and 
is a random sample of the general adult population. The 
cohort comprises a total of 9,656 men and women aged 
18–76 years, born in Denmark and living in the western part 
of the greater Copenhagen. The cohort is merged from two 
cohorts ( DanFunD part one and DanFunD part two) and will 
create the basis for a longitudinal population-based study of 
FSS. Figure 1 illustrates a flowchart of the DanFunD cohort 
consisting of
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•	 DanFunD part one: a 5-year follow-up examination of 
the Health2006 cohort (n=2,163);36
•	 DanFunD part two: a new cohort also dedicated to FSS, 
accomplished from 2012 to 2015 (n=7,493).
DanFunD part one was carried out at RCPH in 2011–2012 
as a follow-up examination of the Health2006 study, which 
is a population-based cohort randomly obtained from the 
nationwide Danish registries and examined at the RCPH 
in the period 2006–2008.36 A total of 3,471 individuals had 
participated in the Health2006 baseline study, of whom 66 
individuals were not eligible for invitation for the follow-up 
examination, and hence 3,405 individuals were invited to 
participate. A total of 2,308 individuals (67.8%) participated 
in the follow-up from 2011 to 2012, with an age span from 
23 to 76 years.
DanFunD part two was carried out at RCPH from 2012 to 
2015. For this new cohort, a total of 25,368 men and women 
aged 18–72 years with the same background population 
characteristics as those of DanFunD part one were randomly 
obtained from the nationwide Danish registries and invited 
to participate. A total of 7,493 (29.5%) individuals agreed 
to participate. A total of 145 individuals participated in both 
DanFunD part one and DanFunD part two, and for those 
individuals, only data obtained from DanFunD part two were 
included in the overall study.
All participants were asked to meet fasting at the day of 
examination and to abstain from smoking at least 1 hour prior 
to examination. Exclusion criteria were as follows: not born 
in Denmark, not being a Danish citizen, and pregnancy. All 
participants had a general health examination and completed 
a premailed questionnaire as well as an additional ques-
tionnaire at RCPH. A written informed consent form was 
obtained from all participants, and the study was approved 
by the Ethical Committee of Copenhagen County (Ethics 
Committee: KA-2006-0011, H-3-2011-081, and H-3-2012-
0015) and the Danish Data Protection Agency.
Plans for follow-up
A follow-up is scheduled to take place in 2017–2020. Fur-
ther reexaminations will be planned, and there are options 
of nested case–control or case–cohort studies in the future. 
The entire (both responders and nonresponders) cohort 
will continuously be followed up in the nationwide Danish 
registries on the development of diseases (both somatic and 
psychiatric), reimbursement of medicine, contact to general 
practitioners, and social factors.
Measurements
The data collection procedure was similar for both DanFunD 
part one and DanFunD part two, and most measures are 
available for the entire merge cohort. Some examinations 
have been included only for DanFunD part two, and the 
numbers of participants for those measures are provided 
where applicable. A summary of all measurements can be 
found in Table 1.
Figure 1 Flowchart of the DanFunD cohort.
Abbreviation: DanFunD, Danish study of Functional Disorders.
Health2006 baseline
7,931 invited
3,471 participated (43.8%)
66 were not eligible for invitation
because of eg, death or emigration
145 participated in both DanFunD
part one and part two.
From those, only data from DanFunD
part two were included
DanFunD cohort (part one + part two)
(2,163+7,493)
9,656 participated (33.7%)
DanFunD part two
(new cohort – year 2012–2015)
25,368 invited
7,493 participated (29.5%)
DanFunD part one
(Health2006 5-year follow-up)
3,405 invited
2,308 participated (67.8%)
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Questionnaires
Validated questions on a number of parameters routinely 
assessed in the RCPH cohorts were measured in a premailed 
questionnaire. Participants were asked questions regarding 
social factors, mental vulnerability,37 general health, use of the 
health care system, occurrence of chronic diseases, and lifestyle 
factors such as smoking, alcohol consumption, physical activ-
ity, sedentarism,36 and dietary intake (estimated using a self-
administered 26-item food frequency questionnaire [FFQ]).38 
Furthermore, validated questionnaires were filled in at RCPH on 
the five-factor personality traits (NEO Five-Factor Inventory),39 
coping resources (general self-efficacy scale),40 self-perceived 
stress (Cohen’s Perceived Stress Scale),41 life events (cumula-
tive lifetime adversity measure, DanFunD part two only),42 
fatigue (the Chalder Fatigue scale),43,44 mental health (Symptom 
Checklist 90 [somatization, anxiety, and depression]),45 health 
anxiety (the Whiteley-7 scale),46 illness perception (Brief Ill-
ness Perception Questionnaire),47 and Kinesiophobia (Tampa 
scale).48 Questionnaires regarding a large variety of relevant 
symptoms were also administered regarding fibromyalgia,49,50 
chronic fatigue syndrome,43 irritable bowel syndrome and dys-
pepsia,7–9 multiple chemical sensitivity,51,52 whiplash-associated 
disorders, and bodily distress syndrome.6,17,53
Interview
To establish FSS diagnosis and validate the symptom question-
naires, a stratified sample of ~10% of all DanFunD part two 
participants (n=706) and all DanFunD part two high scores 
on the bodily distress syndrome symptoms questionnaire17 and 
Whitely-7 scale46 (n=903) completed a diagnostic assessment 
by FSSminiSCAN, which is a brief version of the Schedules 
for Clinical Assessment in Neuropsychiatry.54 The interviews 
were conducted by experienced primary care physicians.
Examinations
Basic physiological examinations
A basic examination routinely conducted in all cohorts at 
RCPH was included55 regarding cardiorespiratory fitness 
(blood pressure, resting heart rate, step test,56 lung function 
by spirometry, and respiratory rate), morphological fitness 
(weight, height, waist and hip circumference, and bioelectri-
cal impedance), and muscle fitness (hand grip).
Cervical range of motion
For the DanFunD part two, a “mobility of the neck” test 
was included, measured by cervical range of motion.57,58 
 Participants were placed in a low, fixed chair without armrest 
Table 1 Summary of data collected for the DanFunD
General questionnaire-based 
information
Social factors, lifestyle factors, physical activity and sedentarism, general health, use of health care system, and 
chronic diseases
Diet Dietary Quality Score based on a self-administered food frequency questionnaire
Mental fitness component Mental vulnerability, somatization, anxiety, and depression, illness perception, health anxiety, life events 
(DanFunD part two), fatigue, personality traits, coping resources, and perceived stress
FSS Fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome and dyspepsia, multiple chemical sensitivity, 
whiplash-associated disorders, and bodily distress syndrome
Diagnostic assessment of FSS Simplified version of the Schedules for Clinical Assessment in Neuropsychiatry interview for FSS and common 
mental disorders (n=1,609 from DanFunD part two)
Morphological fitness and muscle 
fitness
Weight, height, waist and hip circumference, bioelectrical impedance, and hand grip
Cardiorespiratory fitness Blood pressure, resting heart rate, step test, lung function by spirometry, and respiratory rate
Mobility of the neck test Mobility of the neck measured by cervical-range-of-motion (DanFunD part two only)
Metabolic and nutritional 
biomarkers
Glucose, glycated hemoglobin (HbA1c), lipids (total cholesterol, LDL, HDL, and VLDL cholesterol, and 
triglycerides), sodium, alanine aminotransferase, albumin, calcium, carbamide, creatinine, potassium, and eGFR. 
Urine levels of sodium, calcium, albumin, and the albumin/creatinine ratio
Heart rate viability Heart rate viability was measured at rest and during deep breathing (DanFunD part two only) and before and 
during the cold pressor test (n=2,199)
Pain perception Pressure pain thresholds and conditioning pain modulation measures using quantitative sensory testing (n= first 
2,199 participants of DanFunD part two) 
Biobank Serum, plasma, urine, and DNA from the entire cohort and feces (n=2,464, volunteers from DanFunD part two)
Genetics About 800,000 single nucleotide polymorphisms 
Gut microbiome characterization Gut microbiome characterization using 16S ribosomal RNA gene marker sequencing (n=2,464)
Linkage to nationwide Danish 
registries
Hospital admissions – both general and psychiatric, reimbursement of medicine and primary health care, the 
diabetes registry, the cancer registry, and the social registries covering education, income, employment, and 
cohabitation
Abbreviations: DanFunD, Danish study of Functional Disorders; eGFR, estimated glomerular filtration rate; FSS, functional somatic syndromes; LDL, low-density lipoprotein; 
HDL, high-density lipoprotein; VLDL, very-low-density lipoprotein.
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with the cervical-range-of-motion device installed on the 
head. Active head movement in six different directions were 
measured, ie, bending, backward bending, rotation to the right 
and left sides, and side bending to the right and left sides. 
The six measured values were used to compute an overall 
measure of total active cervical range of motion.
Pain perception
A pain modulation test was completed in a subgroup repre-
sented by the first 2,199 individuals examined as part of the 
DanFunD part two. Two quantitative sensory testing methods 
were applied:59,60 manually applied pressure stimulation to 
examine pressure pain thresholds and descending pain con-
trol as assessed by a conditioning pain modulation paradigm 
polymorphisms.61
Heart rate variability
Heart rate variability is used to monitor dynamics of the 
autonomic, cardiac innervation and is used to reflect the 
general tone in the autonomic nervous system (ANS). Heart 
rate variability examined as beat-to-beat variation serves as 
an indirect measure of the ANS.62,63 In DanFunD part two, 
heart rate variability was measured at rest and during deep 
breathing. In the subgroup selected for the pain modula-
tion test, heart rate variability was also monitored before 
and during the cold pressor test to quantify the autonomic 
response to pain.64
Biochemical material and measures
Biobank
A biobank has been established at RCPH including serum, 
plasma, urine, and DNA for the entire cohort and feces for 
a subgroup of DanFunD part two (n=2,464). This biobank 
allows for future hypothesis testing, and various biomarkers 
will be of interest, such as markers for autoimmune diseases, 
infectious disease markers, persistent organic pollutants, 
long-chain fatty acids, and low-grade inflammatory markers.
Metabolic markers
Fasting blood samples and urine were analyzed for metabolic 
markers as listed in Table 1.
Genetics
Genotyping applying Human OmniExpress Bead array has 
been conducted on human leukocyte DNA from the entire 
cohort, covering ~800,000 single nucleotides subsequently. 
The genotyping data have been imputed from national and 
international genotype panels.
Gut microbiome characterization
The fecal samples were collected under standardized condi-
tions, and microbial DNA has been extracted for 16S rRNA 
gene marker studies of the gut microbiome (n=2,464). Ali-
quots of feces have been stored in a research biobank for 
subsequent analysis of fecal biomarkers and metabolites.
Registries
The entire DanFunD cohort including responders and non-
responders is linked to the nationwide Danish registries 
using the unique person number system (The Danish Civil 
Registration System) making individual linkage possible. 
These registries cover hospital admissions and outpatient 
contacts – both general and psychiatric – reimbursement of 
medicine, use of primary health care, and a variety of social 
parameters (eg, education, income, employment, cohabita-
tion, and ethnicity). The cohort will similarly be linked to 
the Danish diabetes registry and cancer registry.
Cohort characteristics  
and ongoing projects
Selected characteristics of the DanFunD cohort are depicted 
in Table 2 (lifestyle factors), Table 3 (self-reported symptoms 
commonly associated with FSS), and Table 4 (self-reported 
FSS), providing an overview of parameters of relevance 
for FSS research. As described in the following sections, a 
number of projects using DanFunD data have already been 
initiated to fulfill the primary objectives, and findings will 
be published in the coming years. A theoretical framework 
for the development of FSS has been computed as depicted 
in Figure 2, and as more knowledge about various aspects 
of FSS becomes available, new hypotheses will be tested.
Delimitation of FSS 
This part follows the following two integrated trails: valida-
tion of the various classical definitions of FSS based on an 
FSSminiSCAN interview for FSS in a nested case-based 
design54 and the use of advanced statistical methods and an 
exploratory approach to identify and describe the associa-
tions among somatic symptoms, showing the frequency of 
symptoms and how they are associated in a complex structure. 
Findings from the two parallel trails will be used to assess 
whether other delimitations of FSS may be more relevant 
than currently available.65
Pathogenic pathways
ANS is suspected to be a central player in FSS pathologies, 
with altered ANS reactivity being associated with chronic 
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Table 4 Self-reported functional somatic syndromesa,b
Variables Men, age (years), n (%) Women, age (years), n (%)
Allb 
(3,456)
18–39 
(602)
40–49 
(677)
50–59 
(894)
60–72 
(1,283)
Allb 
(4,037)
18–39 
(734)
40–49 
(872)
50–59 
(1,097)
60–72 
(1,334)
Fibromyalgia 7 (0.2) 1 (0.2) 1 (0.1) 4 (0.5) 1 (0.1) 52 (1.3) 5 (0.7) 16 (1.8) 14 (1.3) 17 (1.3)
Irritable bowel 
syndrome 
261 (7.7) 18 (3.0) 42 (6.3) 70 (7.9) 131 (10.5) 602 (15.1) 82 (11.3) 95 (10.9) 170 (15.8) 255 (19.6)
Chronic fatigue 
syndrome 
39 (1.1) 4 (0.7) 1 (0.1) 14 (1.6) 20 (1.6) 50 (1.3) 4 (0.6) 13 (1.5) 13 (1.2) 20 (1.5)
Multiple chemical 
sensitivity 
36 (1.1) 2 (0.3) 0 (0.0) 6 (0.7) 28 (2.2) 124 (3.1) 13 (1.8) 15 (1.7) 34 (3.2) 62 (4.8)
Whiplash-
associated 
disorders 
71 (2.1) 17 (2.8) 16 (2.4) 18 (2.1) 20 (1.6) 146 (3.7) 21 (2.9) 39 (4.5) 51 (4.7) 35 (2.7)
Report one of the 
above 
344 (10.0) 40 (6.6) 51 (7.5) 84 (9.4) 169 (13.2) 678 (16.8) 102 (13.9) 117 (13.4) 199 (18.1) 260 (19.5)
Report two or 
more of the above 
31 (0.9) 1 (0.2) 4 (0.6) 12 (1.3) 14 (1.1) 134 (3.3) 11 (1.5) 28 (3.2) 36 (3.3) 59 (4.4)
Notes: aHave you ever been told by a physician that you suffer from any of the following conditions? bQuestion about self-reported functional somatic syndromes were only 
included in DanFunD part two.
Abbreviation: DanFunD, Danish study of Functional Disorders.
Figure 2 A theoretical framework for development of FSS.
Abbreviation: FSS, functional somatic syndromes.
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pain and sympathetic predominance found in conditions such 
as fibromyalgia, chronic fatigue syndrome, and irritable bowel 
syndrome.62,63,66,67 The functioning of the ANS is studied by 
means of heart rate variability as an indirect measure of ANS 
functioning. Persistent pain is similarly common in most FSS, 
and changes in pain sensitivity are frequently reported.10,13,30,68,69 
The status of specific pain mechanisms can be assessed experi-
mentally by standardized activation of different pathways in the 
nociceptive system and quantitative assessment of the evoked 
responses, also known as quantitative sensory testing. By 
means of heart rate viability and quantitative sensory testing 
measures, the role of and interplay between altered pain percep-
tion, regulation of ANS, and a number of relevant biomarkers 
will be examined in relation to the pathophysiology of FSS.
Risk factors
The analysis of risk factors will comprise a broad range of 
physical, emotional, cognitive, social, and health care variables 
(Figure 2). Studies have found that cognitive and behavioral 
factors, such as illness worrying, symptom catastrophizing, 
and pain avoidance behavior, are important risk factors and 
determinants of FSS.32,33,70–72 However, the mechanisms behind 
these associations between psychological factors and FSS, as 
well as the impact of personality, self-efficacy, and perceived 
stress in particular, are still unclear. Analyses will be conducted 
to assess whether personality traits and general self-efficacy act 
as independent risk factors for FSS, and self-perceived stress, 
illness worrying, pain avoidance behavior, and physical activity 
will be investigated as potential mediating factors.
Consequences
Utilizing the improved delimitations of FSS phenotypes 
proposed based on DanFunD, the consequences of FSS will 
be reassessed on an individual level and for the society as a 
whole, focusing on the course of the syndromes, develop-
ment of other diseases, and the socioeconomic consequences. 
Linking to central registries, it will be tested to which extent 
individuals with FSS compared to individuals without FSS 
use the health care system, their use of antidepressive medica-
tion or minor tranquilizers, their incidences of somatic and 
psychiatric diseases, and whether they suffer negative social 
changes (eg, disability pension).73
Strengths and weaknesses
DanFunD is the first attempt in Denmark to bring experts 
within epidemiology, clinicians working with FSS, and basic 
researchers and biostatisticians together in a joint effort 
to unravel the epidemiology of FSS by establishing a new 
large population-based cohort dedicated to research in FSS. 
Succeeding the data collection procedure, a comprehensive 
and coordinated research plan will be anchored in the epi-
demiological institution, RCPH, creating the fundament for 
research into the epidemiology of FSS for the years to come.
The DanFunD has some methodological strengths and 
limitations, which should be considered when analyzing 
and interpreting future data and implications of results. An 
important strength of this study is the large random sample 
recruited from the general adult population using the nation-
wide Danish registries and comprising both men and women 
over a 50-year age span. Furthermore, all data collected are 
based on validated questionnaires and examinations and 
are being linked to national registers, by which participants 
can be followed and their data updated lifelong. Finally, the 
biobank makes it possible to test the upcoming hypothesis.
A concern is the relatively low rate of participation 
( Figure 1), which is a general trend in these years. Fur-
thermore, some differences between responders and non-
responders are also expected. A nonresponder analyses of 
the Health2006 (baseline) study stated that nonresponders 
differed from responders with respect to sociodemographic 
characteristics, education, and use of health services. 
 Nonresponders had lower socioeconomic status, lower 
educational attainment, and lower personal income,36 and 
the same characteristics are expected to be applicable to 
the DanFunD cohort as well. However, we will be able to 
perform weighted analyses using the information obtained 
from nationwide Danish registries, which includes data from 
both the responders and the nonresponders.
Steering committee
DanFunD is anchored at RCPH. The center has >50 years 
of experience in conducting large-scale population-based 
surveys and epidemiological research as well as a perma-
nent staff capable of conducting large-scale data collections 
in the general population. The principal investigator of the 
DanFunD, Torben Jørgensen, from RCPH leads the coordi-
nation of projects and activities and is responsible for the 
operation of DanFunD, including scientific, administrative, 
financial, ethics, and communication tasks. The steering com-
mittee consists of Professor Torben Jørgensen, Professor Per 
Fink, senior scientist Sine Skovbjerg, chief physician Jesper 
Mehlsen, and chief physician Lene Falgaard Eplov. The steer-
ing committee reviews the scientific progress and oversees 
the direction and progress of the scientific objectives.
Access to data
The DanFunD includes a growing number of national and 
international collaborating research partners representing 
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various areas of expertise. It is the ambition with DanFunD 
to use a multidisciplinary approach in order to fulfill its 
objectives, and all researchers with an interest in the field 
of FSS and a high quality research proposal are encouraged 
to make contact. Access to data and biological material can 
be granted by the DanFunD steering committee. Submitted 
applications must be accompanied by a research proposal that 
comply with  Danish regulations on ethical approval and data 
protection. For more information, please contact DanFunD 
administrative and scientific officer Thomas Dantoft or visit 
our webpage at http://www.danfund.org.
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